AR064571A1 - PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER. - Google Patents

PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.

Info

Publication number
AR064571A1
AR064571A1 ARP070105940A ARP070105940A AR064571A1 AR 064571 A1 AR064571 A1 AR 064571A1 AR P070105940 A ARP070105940 A AR P070105940A AR P070105940 A ARP070105940 A AR P070105940A AR 064571 A1 AR064571 A1 AR 064571A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
cycloalkyl
alkoxy
alkynyl
Prior art date
Application number
ARP070105940A
Other languages
Spanish (es)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of AR064571A1 publication Critical patent/AR064571A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Compuestos pirimidínicos sustituidos en la posicion 2, caracterizado porque tiene la formula 1, y sus sales aceptables en farmacia, para el uso en terapia: en la que los índices y los sustituyentes son tal como se definen a continuacion: n representa 1, 2, 3, 4 o 5; L representa halogeno, ciano, cianato (OCN), alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-6, alqueniloxi C2-10, alquiniloxi C2-10, cicloalquilo C3-6, cicloalquenilo C4-6, cicloalquiloxi C3-6, cicloalqueniloxi C4-6, nitro, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, -C(=S)-N(A2)A1, -C(=NA2)-SA1, C(A2)(=N-OA1), N(A2)A1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=O)m-A1, S(=O)m-O-A1 o S(=O)m-N(A2)A1, en los que m representa 0, 1 o 2; A1, A2, A3, independientemente unos de otros, representan hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8 o fenilo, en los que los restos orgánicos pueden estar parcial o totalmente halogenados o pueden estar sustituidos por halogeno, nitro, cianato, ciano y/o alcoxi C1-4 o A1 y A2 juntos con los átomos a los que están unidos representan un heterociclo de cinco o seis miembros, saturado, parcialmente insaturado o aromático que comprende uno, dos, tres o cuatro heteroátomos seleccionados de entre el grupo compuesto de O, N y S, como miembros de anillo; en los que los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones del resto L a su vez pueden estar parcial o totalmente halogenados o pueden portar uno, dos, tres o cuatro restos RL, que pueden ser iguales o diferentes unos de otros: RL representa halogeno, ciano, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, hidroxilo, alcoxi C1-6, alqueniloxi C2-10, alquiniloxi C2-10, cicloaIquilo C3-6, cicloalquenilo C4-6, cicloalcoxi C3-6, cicloalqueniloxi C4-6, -C(=O)-A4, -C(=O)-O-A4, -C(=O)-N(A5)A4, C(A5)(=N-OA4), N(A5)A4, N(A5)-C(=O)A4, N(A6)-C(=O)-N(A5)A4, S(=O)v-A4, S(=O)v-O-A4 o S(=O)v-N(A5)A4, siendo también posible que dos restos RL vecinales juntos representen (=O) o (=S), en los que v representa 0, 1 o 2; A4, A5, A6, independientemente unos de otros, tienen los significados de A1, A2 y A3 tal como están definidos anteriormente; y en los que los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones de los restos RL a su vez pueden estar parcial o totalmente halogenados o portar uno, dos o tres restos RLA, que pueden ser iguales o diferentes unos de otros y que tienen los significados de RL tal como están definidos anteriormente; R1, R2, independientemente el uno del otro, representan alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-12 o cicloalquenilo C4-10 en los que los grupos alifáticos y/o alicíclicos de las definiciones de los restos R1 y R2 a su vez pueden estar parcial o totalmente halogenados o pueden portar uno, dos, tres o cuatro restos Rv, que pueden ser iguales o diferentes unos de otros; Rv representa halogeno, ciano, alquilo C1-8, alquenilo C2- 10, alquinilo C2-10, cicloalquilo C3-6, cicloalquenilo C4-6, hidroxilo, alcoxi C1-6, alqueniloxi C2-10, alquiniloxi C2-10, cicloalquiloxi C 3-6, cicloalqueniloxi C4-6, -C(=O)-A7, -C(=O)-O-A7, -C(=O)-N(A8)A7, C(A8)(=N-OA7), N(A8)A7, N(A8)-C(=O)-A7, N(A9)-C(=O)-N(A8)A7, S(=O)r-A7, S(=O)r-O-A7 o S(=O)r-N(A8)A7, siendo también posible que dos restos Rv vecinales juntos representen (=O) o (=S), o Rv representa fenilo, en el que la fraccion fenilo puede portar uno, dos o tres restos que pueden ser iguales o diferentes unos de otros y que están seleccionados de entre el grupo compuesto de: halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, haloalquilo C1-6, alcoxi C1-6, ciano, nitro, -C(=O)-A, -C(=O)-O-A, -C(=O)-N(A')A, -C(A')(=N-OA) y -N(A')A; en los que r representa 0, 1 o 2; A7, A8, A9, A y A', independientemente unos de otros, tienen los significados de A1, A2 y A3 tal como están definidos anteriormente, y en los que los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones de los restos Rv a su vez pueden estar parcial o totalmente halogenados, R2 adicionalmente puede representar H; R1 y R2 junto con el átomo de N al que están unidos, también pueden formar un anillo saturado o no saturado de 5 o 6 miembros, que puede comprender O, S, un grupo carbonilo -(C=O)-, sulfoxido-(-S[=O]-), un grupo sulfonilo -(SO2-) u otro grupo (-N(Rx)-, como miembro de anillo, en el que Rx representa H o alquilo C1-6, y/o en el que el anillo formado puede comprender uno o más sustituyentes seleccionados de entre el grupo compuesto de halogeno, alquilo C1-6, haloalquilo C1-6 y oxi-alquilenoxi C1-3; R3 representa halogeno, ciano, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, alcoxi C1-4, alqueniloxi C3-4, alquiniloxi C3-4, alquil C1-6-tio, di-(alquil C1-6)amino o alquil C1-6-amino, en los que los grupos alifáticos y/o alicíclicos de las definiciones del resto R3 a su vez pueden estar parcial o totalmente halogenados o pueden portar uno, dos, tres o cuatro restos Rt, que pueden ser iguales o diferentes unos de otros; Rt representa halogeno, ciano, alquilo C1-8, alquenilo C2-10, alquinilo C2-10, hidroxilo, alcoxi C1-6, cicloalquilo C3-6, alqueniloxi C2-10, alquiniloxi C2-10, cicloalquenilo C4-6, cicloalquiloxi C3-6, cicloalqueniloxi C4-6, -C(=O)-A10, -C(=O)-OA10, -C(=O)-N(A11)A10, C(A11)(=N-OA10), N(A11)A10, N(A11)-C(=O)-A10, N(A12)-C(=O)-N(A11)A10, S(=O)w-A10, S(=O)w-O-A10 o S(=O)w-N(A11)A10, siendo también posible que dos radicales Rt vecinales juntos representen (=O) o (=S), en los que w representa 0, 1 o 2; A10, A11 y A12, independientemente unos de otros, tienen los significados de A1, A2 y A3 tal como están definidos anteriormente; y en los que los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones de los restos Rt a su vez pueden estar parcial o totalmente halogenados o pueden portar uno, dos o tres restos Rta, que pueden ser iguales o diferentes unos de otros y que tienen los significados de Rt tal como están definidos anteriormente; X representa un grupo -CH-Ra, -N-Rb, -O- o -S-; Ra representa hidrogeno, halogeno, alquilo C1-6, alcoxi C1-6, ciano o alcoxi C1-6-carbonilo; Rb representa hidrogeno, alquilo C1-6 o cicloalquilo C3-6; T representa un grupo -CH-Ra1-; Ra1 independientemente unos de otros, tiene los significados de Ra tal como están definidos anteriormente; q representa 1, 2, 3 o 4; Y representa un grupo -CH-Ra2- o -N-Rb1-; Ra2 tiene los significados de Ra tal como están definidos anteriormente; Rb1 tiene los significados de Rb tal como están definidos anteriormente; o representa 0 o 1; Z representa O, S o un grupo N(Rc); y Rc representa hidrogeno, alquilo C1-6 o alcoxi C1-6.Claim 1: Substituted pyrimidine compounds in position 2, characterized in that it has formula 1, and its pharmaceutically acceptable salts, for use in therapy: in which the indices and substituents are as defined below: n represents 1 , 2, 3, 4 or 5; L represents halogen, cyano, cyanate (OCN), C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-6 alkoxy, C2-10 alkenyloxy, C2-10 alkynyloxy, C3-6 cycloalkyl, C4-6 cycloalkenyl , C3-6 cycloalkyloxy, C4-6 cycloalkenyloxy, nitro, -C (= O) -A1, -C (= O) -O-A1, -C (= O) -N (A2) A1, -C (= S) -N (A2) A1, -C (= NA2) -SA1, C (A2) (= N-OA1), N (A2) A1, N (A2) -C (= O) -A1, N ( A3) -C (= O) -N (A2) A1, S (= O) m-A1, S (= O) mO-A1 or S (= O) mN (A2) A1, where m represents 0 , 1 or 2; A1, A2, A3, independently of each other, represent hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl or phenyl, in which the organic moieties may be partial or fully halogenated or may be substituted by halogen, nitro, cyanate, cyano and / or C1-4 or A1 and A2 alkoxy together with the atoms to which they are attached represent a five or six membered heterocycle, saturated, partially unsaturated or aromatic comprising one, two, three or four heteroatoms selected from the group consisting of O, N and S, as ring members; in which the aliphatic, alicyclic and / or aromatic groups of the definitions of the remainder L in turn may be partially or totally halogenated or may carry one, two, three or four RL moieties, which may be the same or different from each other: RL represents halogen, cyano, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, hydroxy, C1-6 alkoxy, C2-10 alkenyloxy, C2-10 alkynyloxy, C3-6 cycloalkyl, C4-6 cycloalkenyl, C3 cycloalkoxy -6, C4-6 cycloalkenyloxy, -C (= O) -A4, -C (= O) -O-A4, -C (= O) -N (A5) A4, C (A5) (= N-OA4 ), N (A5) A4, N (A5) -C (= O) A4, N (A6) -C (= O) -N (A5) A4, S (= O) v-A4, S (= O ) vO-A4 or S (= O) vN (A5) A4, it being also possible for two neighborhood RL residues together to represent (= O) or (= S), where v represents 0, 1 or 2; A4, A5, A6, independently of each other, have the meanings of A1, A2 and A3 as defined above; and in which the aliphatic, alicyclic and / or aromatic groups of the definitions of the RL moieties may in turn be partially or totally halogenated or carry one, two or three RLA moieties, which may be the same or different from each other and that they have the meanings of RL as defined above; R1, R2, independently of each other, represent C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 cycloalkyl or C4-10 cycloalkenyl group in which the aliphatic and / or alicyclic groups of the definitions of the R1 and R2 residues in turn may be partially or totally halogenated or may carry one, two, three or four Rv residues, which may be the same or different from each other; Rv represents halogen, cyano, C1-8 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, C4-6 cycloalkenyl, hydroxyl, C1-6 alkoxy, C2-10 alkenyloxy, C2-10 alkynyloxy, C cycloalkyloxy 3-6, C4-6 cycloalkenyloxy, -C (= O) -A7, -C (= O) -O-A7, -C (= O) -N (A8) A7, C (A8) (= N- OA7), N (A8) A7, N (A8) -C (= O) -A7, N (A9) -C (= O) -N (A8) A7, S (= O) r-A7, S ( = O) rO-A7 or S (= O) rN (A8) A7, it being also possible that two neighborhood Rv residues together represent (= O) or (= S), or Rv represents phenyl, in which the phenyl fraction can carrying one, two or three residues that may be the same or different from each other and that are selected from the group consisting of: halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, haloalkyl C1-6, C1-6 alkoxy, cyano, nitro, -C (= O) -A, -C (= O) -OA, -C (= O) -N (A ') A, -C (A' ) (= N-OA) and -N (A ') A; in which r represents 0, 1 or 2; A7, A8, A9, A and A ', independently of each other, have the meanings of A1, A2 and A3 as defined above, and in which the aliphatic, alicyclic and / or aromatic groups of the residue definitions Rv in turn may be partially or totally halogenated, R2 may additionally represent H; R1 and R2 together with the N atom to which they are attached, can also form a saturated or unsaturated ring of 5 or 6 members, which may comprise O, S, a carbonyl group - (C = O) -, sulfoxide- ( -S [= O] -), a sulfonyl group - (SO2-) or other group (-N (Rx) -, as a ring member, in which Rx represents H or C1-6 alkyl, and / or in the that the ring formed may comprise one or more substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl and C1-3 oxy-alkyleneoxy; R3 represents halogen, cyano, C1-4 alkyl, C2 alkenyl 4, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, C3-4 alkenyloxy, C3-4 alkynyloxy, C1-6-thio alkyl, di- (C1-6 alkyl) amino or C1-6-alkyl alkyl , in which the aliphatic and / or alicyclic groups of the definitions of the R3 moiety in turn may be partially or totally halogenated or may carry one, two, three or four Rt moieties, which may be the same or different from each other; Rt represents halogen, cyano, C1-8 alkyl, alq C2-10 uenyl, C2-10 alkynyl, hydroxy, C1-6 alkoxy, C3-6 cycloalkyl, C2-10 alkenyloxy, C2-10 alkynyloxy, C4-6 cycloalkenyl, C3-6 cycloalkyloxy, C4-6 cycloalkenyloxy, -C ( = O) -A10, -C (= O) -OA10, -C (= O) -N (A11) A10, C (A11) (= N-OA10), N (A11) A10, N (A11) - C (= O) -A10, N (A12) -C (= O) -N (A11) A10, S (= O) w-A10, S (= O) wO-A10 or S (= O) wN ( A11) A10, it being also possible for two neighborhood Rt radicals together to represent (= O) or (= S), in which w represents 0, 1 or 2; A10, A11 and A12, independently of each other, have the meanings of A1, A2 and A3 as defined above; and in which the aliphatic, alicyclic and / or aromatic groups of the definitions of the Rt moieties in turn can be partially or totally halogenated or can carry one, two or three Rta moieties, which may be the same or different from each other and which have the meanings of Rt as defined above; X represents a group -CH-Ra, -N-Rb, -O- or -S-; Ra represents hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano or C 1-6 alkoxycarbonyl; Rb represents hydrogen, C1-6 alkyl or C3-6 cycloalkyl; T represents a group -CH-Ra1-; Ra1 independently of each other, has the meanings of Ra as defined above; q represents 1, 2, 3 or 4; Y represents a group -CH-Ra2- or -N-Rb1-; Ra2 has the meanings of Ra as defined above; Rb1 has the meanings of Rb as defined above; or represents 0 or 1; Z represents O, S or a group N (Rc); and Rc represents hydrogen, C1-6 alkyl or C1-6 alkoxy.

ARP070105940A 2006-12-28 2007-12-27 PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER. AR064571A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127316 2006-12-28

Publications (1)

Publication Number Publication Date
AR064571A1 true AR064571A1 (en) 2009-04-08

Family

ID=39023533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105940A AR064571A1 (en) 2006-12-28 2007-12-27 PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.

Country Status (4)

Country Link
AR (1) AR064571A1 (en)
CL (1) CL2007003847A1 (en)
TW (1) TW200833342A (en)
WO (1) WO2008080937A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20166432B (en) * 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
AU2014229283B2 (en) * 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
WO2018118793A1 (en) * 2016-12-19 2018-06-28 Isocure Biosciences Inc. Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100347267B1 (en) * 1999-07-06 2002-11-16 주식회사 경인제약 Functional beverage containing submerged culture broth of Paecilomyces sp. and process for preparation thereof
US7820647B2 (en) * 2004-05-19 2010-10-26 Basf Aktiengesellschaft 2-substituted pyrimidines and their use as pesticides

Also Published As

Publication number Publication date
WO2008080937A1 (en) 2008-07-10
CL2007003847A1 (en) 2008-04-18
TW200833342A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
AR064571A1 (en) PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.
AR058587A1 (en) PIRROLO-1,5-NAFTIRIDINONE COMPOUNDS, ITS USE AS ANTIBACTERIAL AGENTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND INTERMEDIARY COMPOUNDS TO PREPARE SUCH COMPOUNDS
AR056199A1 (en) DERIVATIVES OF 8-OXOADENINE 9-SUBSTITUTED
AR058287A1 (en) ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION
AR060658A1 (en) DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
AR057131A1 (en) PURINE DERIVATIVES AS IMMUNOMODULATOR
AR038240A1 (en) PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE FOR PREPARATION
PE20060691A1 (en) SERINAMIDES REPLACED BY BENZOYL
AR053195A1 (en) INHIBITING COMPOUNDS OF DIPEPTIDIL PEPTIDASA-IV METHODS TO PREPARE THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE AGENT
AR059957A1 (en) DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
AR064246A1 (en) DERIVATIVES OF 5H-PIRIMIDO [5,4-D] [2] INHIBITING BENZAZEPINES OF THE MYTHICAL PROGRESSION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTICANCER AGENTS.
AR046779A1 (en) DERIVATIVES OF PIRAZOL, METHODS FOR THEIR PREPARATION AND USES OF THE SAME IN THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND MEDICINES CONTAINING THEM WITH TRK INHIBITORY ACTIVITY FOR THE TREATMENT OR PROFILAXIS OF CANCER.
AR053092A1 (en) COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS
ECSP10010585A (en) COMPOUNDS OF 2- IMIDO- 3- METHYL PIRROID PYRIMIDINONE PHENYL- REPLACED AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE
AR086367A1 (en) PIRROLIDINIL UREA AND PIRROLIDINIL TIOUREA COMPOUNDS AS TRKA CINASE INHIBITORS
PE20090042A1 (en) CYCLOPAMINE ANALOGS
AR049861A1 (en) BENCIMIDAZOL DERIVATIVES, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT CONNECT THEM.
PE20130149A1 (en) DERIVATIVES OF CHROMENONE WITH ANTI-TUMOR ACTIVITY
AR036604A1 (en) DERIVATIVES OF 4-PIRIMIDONA 3-SUBSTITUTED
UY29301A1 (en) AMIDA DERIVATIVES
AR064889A1 (en) DERIVATIVES OF PYRIDOPIRIMIDINES, A METHOD FOR THEIR PREPARATION, A COMPOSITION AND A PHARMACEUTICAL PRODUCT THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY PDE-4
AR036599A1 (en) A DERIVATIVE OF 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPIRIMID [1,2-A] PYRIMIDIN-4-ONA AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO [1,2-A] PYRIMIDIN-5 (1H ) ONA SUBSTITUTED, USE OF THE SAME, A MEDICINAL PRODUCT THAT INCLUDES IT AND AN INHIBITOR OF GSK3BETA OR GSK3BETA AND CDK5 / P25 SELECTED BETWEEN THE DERIVATIVE GROUP OF SAID
PE20141352A1 (en) PHENYL-3-AZA-BICYCLE [3,1,0] HEX-3-IL-METHANONES AND ITS USE AS A MEDICINAL PRODUCT
AR086086A1 (en) GLUCOSID DERIVATIVES AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure